Patients with ovarian or peritoneal cancers are needed for a study to research a hormonal drug therapy

UVA Tracking #
Principal Investigator
Kari E Ring
Rachel Lacy
Contact Email
Contact Phone
Official Trial Title
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have low-grade serous carcinoma of the ovary or peritoneum. The purpose of this study to evaluate if the use of a hormonal drug, either by itself or by adding it to the usual chemotherapy drugs, can lower the chance of your cancer growing or spreading.

Your participation will continue as long as the treatment is helping you. The follow-up after treatment could last up to 10 years. Study specific tests that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: